The prevalence and distribution of AIDS-related Kaposi's sarcoma (KS) suggest that a sexually transmitted infectious agent is an important cofactor in its development in the immunocompromised host.
reading frames have been implicated in its oncogenic potential (eg, cyclin D homolog, viral IL-6, and a Glike protein). [7] [8] [9] [10] The sequences are homologous to other Gammaherpesvirinae subfamily members, particularly to two oncogenic viruses, Epstein-Barr virus-associated with endemic Burkitt's lymphomas and nasopharyngeal carcinoma in humans as well as Herpesvirus Saimirii associated with lymphomas in new-world monkeys. 11 An important question is the relationship between seroprevalence of HHV-8 and the emergence of HHV-8-related diseases. Because a low virus load in latency is characteristic of the Gammaherpesvirinae subfamily and precludes easy detection by polymerase chain reaction (PCR), the prevalence and distribution of the virus are best studied by the detection of specific antibodies. A number of investigators studied the seroprevalence of HHV-8 antibodies in groups with increased risk of KS, and the seroprevalence rates in HIV-positive, homosexual men have r a n g e d b e t w e e n 3 1 % a n d 9 3 % . 1 2 -1 4 Methods using multiple viral antigens for detection of HHV-8 antibodies have proved to be more sensitive than those using recombinant HHV-8 proteins. 15, 16 Said et al 17 established a human body cavity lymphoma cell line (KS-1), which was infected only with HHV-8. By using these cells as a source of viral antigens, we developed an indirect immunofluorescence assay for the detection of anti-HHV-8 antibodies. In a retrospective study, we analyzed blinded serum samples from a cohort of 75 HIV-positive asymptomatic persons (72 homosexual or bisexual men) for the presence of anti-HHV-8 antibodies. We then compared the clinical history and course of the HHV-8-positive and HHV-8-negative groups with special emphasis on CD4 counts and the development of KS.
MATERIALS AND METHODS

Patients
HIV-positive serum samples-All patients included in this study were enrolled in a double-blinded clinical trial comparing two doses of AZT (now known as zidovudine) with placebo in asymptomatic HIV-positive persons between 1989 and 1991. Serum samples were obtained from 75 patients after informed consent and stored at -20°C for future studies. The anonymous correlation of HHV-8 serum data with available clinical data was performed in accordance with the guidelines of the human subject protection committee at the University of California, Los Angeles.
Healthy donors-An age-matched control group was obtained from 40 healthy blood donors at CedarsSinai Medical Center, Los Angeles. Three serum samples from patients with Castleman's disease were received from Showa University, Tokyo, and two samples from Cedars-Sinai Medical Center, Los Angeles.
The cell line KS-1 was previously established from the pleural fluid of an HIV-positive patient with body cavity-based lymphoma. 17 The cell line was shown to be positive for HHV-8 and negative for HIV and EBV KS-1 cells were used as a source of viral antigens for the development of an indirect immunofluorescence assay for anti-HHV-8 antibodies.
Immunofluorescence assay-KS-1 cells were grown in RPMI 1640 supplemented with 20% fetal calf serum, 100 U / m L of penicillin, and 100 u g / m L of streptomycin. Cells were treated with 10 n g / m L o-tetradecanoylphorbol-13-acetate (TPA, Sigma, St Louis, Mo) for 72 hours; subsequently cytospins were prepared with 10 5 cells per slide. Cells were air dried and fixed in ice-cold methanol/acetone (1:1) for 2 minutes. After a brief rinse with phosphate-buffered saline (PBS), slides were stored at -20°C. Likewise, cytospins were prepared with untreated KS-1 cells.
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Electron Microscopy
Electron microscopy was performed on cells before and after TPA stimulation to document increased viral expression and correlate with the immunofluorescence assay. Briefly, cells were pelleted, fixed in glutaraldehyde, embedded in epon, and sectioned for electron microscopy u s i n g m e t h o d s p r e v i o u s l y described. 17 Ultrathin sections were counterstained with uranyl acetate and lead citrate and examined with a JEM-100B electron microscope (JEOL, Japan). 17 previously reported the establishment of the cell line KS-1, which is infected by HHV-8 only. KS-1 cells were used as a source of viral antigens for an immunofluorescence assay of HHV-8 antibodies. Serum samples from patients with AIDS-related KS gave a characteristic patchy fluorescence pattern with nuclear localization in untreated KS-1 cells. This was attributed to the presence of antibodies to latent nuclear antigens. A more intense cytoplasmic fluorescence was found when KS-1 cells were pretreated with TPA (Fig) . By electron microscopy the appearance of cytoplasmic fluorescence was directly attributed to the ability of TPA to induce viral production (lytic cycle antigens).
RESULTS
Said et al
We validated the immunofluorescence assay in a small group of patients with AIDS-related KS. Six of six patients had IgG antibodies to latent and lytic antigens with high titers between 1:320 and 1:1,080. In addition, we tested five HIV-negative patients with multicentric Castleman's disease of whom one tested positive for HHV-8 a n t i b o d i e s , and two of two 
HHV-8 in HIV-Positive Persons
HIV-positive patients with primary effusion lymphoma were seropositive for HHV-8 antibodies.
Because strong evidence suggests that the infectious cofactor for AIDS-related KS predicted by epidemiologic studies is HHV-8, 6 we studied the serop r e v a l e n c e of HHV-8 a n t i b o d i e s in a g r o u p 75 asymptomatic HIV-positive persons. A total of 56% (42/75) of the HIV-positive asymptomatic persons were also seropositive for HHV-8.
Of the population, 47% (35/75) showed positivity for IgG antibodies binding to HHV-8 latent and lytic antigens. In addition, 9% (7/75) had antibodies only to lytic antigens. With the exception of two HIV-positive women (both HHV-8-negative) and one heterosexual intravenous drug user (HHV-8-negative), all men were homosexual or bisexual (42/72; 58% HHV-8-positive). In forty HIV-negative age-matched controls, 12% (5/40) were seropositive for HHV-8.
The HIV-negative HHV-8-positive persons had a low HHV-8 antibody titer (<1:40). The HIV-positive persons had a wide variation in HHV-8 antibody titers ranging from 1:40 to 1:1,080, with 60% of these above 1:160. Titers did not correlate with CD4 counts. The HHV-8-positive and HHV-8-negative groups did not differ in age (mean, 38 years), time elapsed from detection of HIV-positivity to sample (mean, 45 months), or follow up (median, 30 months). A history of sexually transmitted diseases was frequent in both groups but almost always present in the HHV-8-positive group (HHV-8-positive group: 92% (24/26) vs 55% (10/18) with sufficient records in HHV-8-negative group) ( Table 1) .
The median CD4 counts at the sample date and at the date of last patient contact were significantly lower in the HHV-8-positive group compared with the HHV-8-negative group (520/^L vs 668 /uL [P = .01]). However, the percentage decrease of CD4 cells during the time of follow-up did not show a significant difference (-32.3% vs -23.8%, P = .48) ( Table 2) . In nine patients, CD4 counts less than 200/uL developed during the follow-up period; all were positive for HHV-8. In two of these nine persons, KS developed, in one patient at 8 months after the HHV-8-positive sample, and in the second patient at 50 months after the HHV-8-positive sample. One HHV-8-positive p a t i e n t died of a generalized infection with Mycobacterium avium-intracellulare; clinically apparent KS had not developed. The longest follow-up of an HIV-positive HHV-8-positive person without the development of KS was 81 months (6 3 /4 years).
DISCUSSION
H u m a n herpesvirus 8 has been associated with classic KS, as well as AIDS-related KS. 5 ' 19 In this study, we determined the seroprevalence of HHV-8 antibodies in banked serum samples from asymptomatic HIV-positive persons enrolled in a clinical trial comparing two doses of AZT and placebo. Patients began the trial between October 1, 1989 and April 1, 1991. Our data support the notion that HHV-8 is a sexually transmitted agent with an especially high prevalence in the homosexual population. We found antibodies against HHV-8 latent nuclear antigens (LANA) in 46% (35/75) of the asymptomatic HIV-positive patients in the Los Angeles area. The previously reported seroprevalence of LANA in other cohorts ranged between 22% and 35%. [12] [13] [14] In approximately 14 recently reported that 90% of an HIV group was HHV-8 seropositive in the San Francisco area. Differences may be assay related; cell line and duration of TPA treatment varied between the studies. In addition, patients in our study may have been studied at an earlier time point. Gao et al 20 found a continuous increase in HHV-8 seropositivity before the onset of KS.
Our results suggest that HHV-8 is acquired early during the course of the HIV infection or even before the infection in a high percentage of cases. A contribution of HIV-related immunosuppression to HHV-8 transmission is therefore unlikely. The duration of HHV-8 infection without the development of KS can be long, at least 6 3 A years. A high percentage of seropositivity implies that KS does not develop in all seropositive patients, which is exemplified by one HHV-8-positive patient who died of infectious complications. Recent epidemiologic data show that the incidence of KS at the diagnosis of AIDS decreased from 31% to 13% in recent years 21 ; CD4 counts less than 200/uL are the major risk factor for the development of KS. At least two epidemiologic studies indicate that the administration of foscarnet or ganciclovir may decrease the risk of KS in HIV-positive persons, possibly postponing the onset until a higher degree of HIV-related i m m u n o s u p p r e s s i o n is reached. 22 ' 23 This was reflected by the low incidence of KS in our study population. Both patients in whom KS developed had CD4 counts less than 200/uL. Interestingly, the median CD4 count in the HHV-8-positive group was significantly lower than in the HHV-8-negative group at the time of the serum sample and at the time of last patient contact. Whitby et al 24 reported a lower CD4 count in HIV-positive persons without KS who had PCR-detectable HHV-8 sequences in the peripheral blood specimens. These researchers suggested that a higher viral load in these persons was due to a reduced immunologic surveillance that facilitated emergence of PCR-detectable HHV-8. Although we cannot exclude the possibility that this could also influence the emergence of detectable antibody titers, we did not find a relationship between anti-HHV-8 titers and CD4 counts in the HHV-8-positive group. High titers were observed in patients with high or low CD4 counts (data not shown). Although the time elapsed after the first positive HIV test result was comparable for both groups, we cannot rule out that the actual duration of HIV infection was longer for the HHV-8-positive group.
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Because HIV and HHV-8 are sexually transmitted diseases, those with more sexual partners would be more likely to become infected with HHV-8 and to have been infected earlier with HIV. Consistent with this, the percentage of decrease of CD4 cells during the foll o w -u p (30 months) did not differ significantly between the groups.
Our study results are consistent with the notion that HHV-8 is a common infection in this group at risk for KS, as it is in other risk groups. The duration of latent infection does not seem to be decisive for the development of KS. Immunosuppression below a certain threshold most likely is the critical factor that allows the manifestation of the oncogenic potential of HHV-8 and determines the clinical development of KS.
